OpenLB
Open Library of Bioscience
Advanced Search
Translational research : the journal of laboratory and clinical medicine
02, 2023;252 21-33.

NLRP3 inflammasome in neurodegenerative disease.

Faith L Anderson, Karl E Biggs, Brynn E Rankin, Matthew C Havrda
Author Information
  1. Faith L Anderson: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire.
  2. Karl E Biggs: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire.
  3. Brynn E Rankin: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire.
  4. Matthew C Havrda: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire. Electronic address: matthew.c.havrda@dartmouth.edu.
PMID: 35952982 DOI: 10.1016/j.trsl.2022.08.006

Abstract

Neurodegenerative diseases are characterized by a dysregulated neuro-glial microenvironment, culminating in functional deficits resulting from neuronal cell death. Inflammation is a hallmark of the neurodegenerative microenvironment and despite a critical role in tissue homeostasis, increasing evidence suggests that chronic inflammatory insult can contribute to progressive neuronal loss. Inflammation has been studied in the context of neurodegenerative disorders for decades but few anti-inflammatory treatments have advanced to clinical use. This is likely due to the related challenges of predicting and mitigating off-target effects impacting the normal immune response while detecting inflammatory signatures that are specific to the progression of neurological disorders. Inflammasomes are pro-inflammatory cytosolic pattern recognition receptors functioning in the innate immune system. Compelling pre-clinical data has prompted an intense interest in the role of the NLR family pyrin domain containing 3 (NLRP3) inflammasome in neurodegenerative disease. NLRP3 is typically inactive but can respond to sterile triggers commonly associated with neurodegenerative disorders including protein misfolding and aggregation, mitochondrial and oxidative stress, and exposure to disease-associated environmental toxicants. Clear evidence of enhanced NLRP3 inflammasome activity in common neurodegenerative diseases has coincided with rapid advancement of novel small molecule therapeutics making the NLRP3 inflammasome an attractive target for near-term interventional studies. In this review, we highlight evidence from model systems and patients indicating inflammasome activity in neurodegenerative disease associated with the NLRP3 inflammasome's ability to recognize pathologic forms of amyloid-β, tau, and α-synuclein. We discuss inflammasome-driven pyroptotic processes highlighting the potential utility of evaluating extracellular inflammasome-related proteins in the context of biomarker discovery. We complete the report by pointing out gaps in our understanding of intracellular modifiers of inflammasome activity and mechanisms regulating the resolution of inflammasome activation. The literature review and perspectives provide a conceptual platform for continued analysis of inflammation in neurodegenerative diseases through the study of inflammasomes and pyroptosis, mechanisms of inflammation and cell death now recognized to function in multiple highly prevalent neurological disorders.

References

Glia. 2020 Feb;68(2):407-421 [PMID: 31596526]
J Neuroinflammation. 2020 Jul 17;17(1):213 [PMID: 32680528]
Lancet Neurol. 2020 Oct;19(10):804-805 [PMID: 32949534]
Science. 2018 Nov 23;362(6417):956-960 [PMID: 30467171]
PLoS One. 2018 Dec 31;13(12):e0210128 [PMID: 30596792]
Inflammopharmacology. 2018 Feb;26(1):77-86 [PMID: 28965161]
Brain Pathol. 2017 Mar;27(2):213-219 [PMID: 27997058]
Nat Neurosci. 2016 Dec;19(12):1599-1609 [PMID: 27820602]
Alzheimers Dement. 2020 Mar 10;: [PMID: 32157811]
J Immunol. 2010 May 1;184(9):4610-4 [PMID: 20368281]
Cell Death Differ. 2019 Jan;26(2):213-228 [PMID: 29786072]
Brain Behav Immun. 2017 Mar;61:306-316 [PMID: 28003153]
Front Immunol. 2019 Nov 01;10:2578 [PMID: 31736980]
Int J Mol Sci. 2020 Jun 30;21(13): [PMID: 32630059]
PLoS One. 2013;8(1):e55375 [PMID: 23383169]
J Pathol. 2022 Mar;256(3):262-268 [PMID: 34883532]
Mol Biol Rep. 2014 Mar;41(3):1653-8 [PMID: 24402877]
Nat Rev Immunol. 2020 Mar;20(3):143-157 [PMID: 31690840]
Exp Mol Med. 2019 Jul 23;51(7):1-13 [PMID: 31337751]
EMBO J. 2018 Jul 13;37(14): [PMID: 29898893]
Nature. 2012 Jan 18;481(7381):278-86 [PMID: 22258606]
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15): [PMID: 33833060]
Int J Mol Sci. 2021 Mar 03;22(5): [PMID: 33802349]
Nature. 1991 Feb 21;349(6311):704-6 [PMID: 1671712]
Neurology. 1990 Nov;40(11):1735-9 [PMID: 2234430]
J Exp Med. 1992 Apr 1;175(4):993-1002 [PMID: 1348083]
Science. 2003 Oct 31;302(5646):841 [PMID: 14593171]
Mult Scler. 2004 Oct;10(5):482-7 [PMID: 15471361]
J Neuroimmunol. 2002 Aug;129(1-2):197-204 [PMID: 12161036]
JAMA. 2005 May 25;293(20):2496-500 [PMID: 15914750]
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4329-48 [PMID: 19725918]
Cell Death Dis. 2020 May 15;11(5):377 [PMID: 32415059]
Lancet Haematol. 2018 Sep;5(9):e393-e402 [PMID: 30072146]
Acta Neuropathol. 2022 Sep;144(3):393-411 [PMID: 35867112]
Cell Rep. 2021 Sep 21;36(12):109720 [PMID: 34551296]
Cell Death Dis. 2022 Apr 4;13(4):302 [PMID: 35379773]
Nat Genet. 2010 Sep;42(9):781-5 [PMID: 20711177]
Infect Immun. 2005 Apr;73(4):1907-16 [PMID: 15784530]
Lancet. 2011 Feb 19;377(9766):641-9 [PMID: 21292315]
Nat Rev Dis Primers. 2017 Oct 05;3:17071 [PMID: 28980624]
J Neuroimmunol. 2002 May;126(1-2):172-9 [PMID: 12020968]
Front Pharmacol. 2020 Aug 11;11:1238 [PMID: 32903782]
Cell. 2010 Mar 19;140(6):821-32 [PMID: 20303873]
Science. 2012 Nov 16;338(6109):949-53 [PMID: 23161999]
Exp Ther Med. 2021 Nov;22(5):1222 [PMID: 34603519]
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8175-80 [PMID: 9653160]
Arch Neurol. 2003 Aug;60(8):1059-64 [PMID: 12925360]
Cell Biosci. 2019 Mar 27;9:31 [PMID: 30962873]
Neurobiol Dis. 2004 Apr;15(3):601-9 [PMID: 15056468]
Nature. 2019 Nov;575(7784):669-673 [PMID: 31748742]
Cancer Cell. 2014 Aug 11;26(2):288-300 [PMID: 25117714]
Cell Death Dis. 2014 Aug 21;5:e1382 [PMID: 25144717]
EMBO Mol Med. 2016 Jun 01;8(6):595-608 [PMID: 27025652]
J Cell Biol. 2016 Jun 20;213(6):617-29 [PMID: 27325789]
Front Aging Neurosci. 2015 Jul 20;7:124 [PMID: 26257642]
Inflammation. 2018 Feb;41(1):93-103 [PMID: 28936769]
Immunology. 2010 Feb;129(2):154-69 [PMID: 20561356]
J Mol Biol. 2019 Aug 9;431(17):3229-3245 [PMID: 31181290]
Nat Rev Drug Discov. 2016 Aug;15(8):551-67 [PMID: 27020098]
J Neuroinflammation. 2020 Jan 8;17(1):11 [PMID: 31915018]
Science. 2022 Jan 21;375(6578):296-301 [PMID: 35025605]
Immunity. 2011 Feb 25;34(2):213-23 [PMID: 21349431]
Acta Neuropathol. 2019 Apr;137(4):599-617 [PMID: 30721409]
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9 [PMID: 15451224]
Eur J Immunol. 2018 Apr;48(4):584-592 [PMID: 29274245]
Toxicol Lett. 2021 Oct 1;349:1-11 [PMID: 34052309]
Nature. 2013 Jan 31;493(7434):674-8 [PMID: 23254930]
J Neuroinflammation. 2016 Jan 27;13:20 [PMID: 26818951]
Oncotarget. 2016 May 10;7(19):28183-94 [PMID: 27058421]
Lancet Rheumatol. 2020 May;2(5):e270-e280 [PMID: 33005902]
Neurology. 2011 Mar 8;76(10):863-9 [PMID: 21368281]
Elife. 2022 Mar 04;11: [PMID: 35244536]
Mech Ageing Dev. 2021 Apr;195:111467 [PMID: 33711349]
Trends Mol Med. 2019 Mar;25(3):198-214 [PMID: 30795972]
Transl Vis Sci Technol. 2020 Dec 17;9(13):27 [PMID: 33364081]
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13046-50 [PMID: 20616033]
Cell Rep. 2020 Mar 17;30(11):3743-3754.e6 [PMID: 32187546]
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73 [PMID: 9600990]
Mol Neurodegener. 2016 Mar 03;11:23 [PMID: 26939933]
Science. 1994 Jun 17;264(5166):1772-5 [PMID: 8209258]
J Immunol. 2010 Jul 15;185(2):974-81 [PMID: 20574004]
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7419-7424 [PMID: 30910980]
EMBO J. 1990 May;9(5):1503-10 [PMID: 2328723]
N Engl J Med. 2006 Mar 2;354(9):942-55 [PMID: 16510748]
Arch Neurol. 2005 Mar;62(3):353-7 [PMID: 15767499]
Nat Med. 2015 Mar;21(3):248-55 [PMID: 25686105]
Nature. 2006 Mar 9;440(7081):228-32 [PMID: 16407890]
Toxicol Sci. 2018 Nov 1;166(1):3-15 [PMID: 30203060]
Nat Commun. 2021 Aug 2;12(1):4664 [PMID: 34341353]
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 [PMID: 12498954]
Science. 1996 Nov 15;274(5290):1197-9 [PMID: 8895469]
J Neuroimmunol. 2014 May 15;270(1-2):56-60 [PMID: 24657029]
Life Sci. 2019 Dec 15;239:117043 [PMID: 31722188]
Arthritis Rheumatol. 2019 Nov;71(11):1955-1963 [PMID: 31161734]
Trends Biochem Sci. 2016 Dec;41(12):1012-1021 [PMID: 27669650]
J Neuroinflammation. 2018 May 1;15(1):129 [PMID: 29716614]
Trends Pharmacol Sci. 2022 Aug;43(8):653-668 [PMID: 35513901]
Neurology. 2020 Oct 13;95(15):e2109-e2118 [PMID: 32641525]
Sci Signal. 2019 Jan 08;12(563): [PMID: 30622196]
Nat Immunol. 2008 Aug;9(8):857-65 [PMID: 18604209]
J Neuroinflammation. 2014 Feb 18;11:32 [PMID: 24548694]
Nature. 2016 Jul 06;535(7610):153-8 [PMID: 27383986]
Circ Res. 2014 Oct 24;115(10):875-83 [PMID: 25185259]
Biochim Biophys Acta Proteins Proteom. 2019 Oct;1867(10):890-908 [PMID: 30853581]
Eur J Neurol. 2020 Oct;27(10):1918-1929 [PMID: 32526057]
Nature. 2017 Dec 20;552(7685):355-361 [PMID: 29293211]
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32145-32154 [PMID: 33257576]
J Clin Invest. 2015 Feb;125(2):665-80 [PMID: 25574840]
Sci Adv. 2020 Dec 4;6(49): [PMID: 33277246]
J Neurochem. 2020 Dec;155(6):650-661 [PMID: 31872431]
PLoS One. 2015 Jun 19;10(6):e0130624 [PMID: 26091541]
J Cell Sci. 2016 May 1;129(9):1928-39 [PMID: 27006116]
Nat Immunol. 2022 May;23(5):692-704 [PMID: 35484407]
J Immunol. 2015 Dec 15;195(12):5718-24 [PMID: 26546608]
Immunity. 2018 Jan 16;48(1):35-44.e6 [PMID: 29195811]
Nat Immunol. 2005 Dec;6(12):1191-7 [PMID: 16369558]
EMBO Mol Med. 2019 Jun;11(6): [PMID: 31015277]
Cell Death Differ. 2019 Jan;26(1):146-161 [PMID: 29666477]
Glia. 2015 Dec;63(12):2260-73 [PMID: 26200799]
Am J Hum Genet. 1999 Oct;65(4):1054-9 [PMID: 10486324]
Mol Neurobiol. 2018 Mar;55(3):2350-2361 [PMID: 28357805]
Physiol Rev. 2015 Oct;95(4):1205-40 [PMID: 26336031]
AIDS. 2018 Jan 28;32(3):299-307 [PMID: 29135573]
Mol Neurobiol. 2017 Aug;54(6):4292-4302 [PMID: 27339879]
Neuropharmacology. 2019 Dec 1;160:107661 [PMID: 31181224]
J Clin Invest. 2010 May;120(5):1368-79 [PMID: 20440079]
Trends Biochem Sci. 2017 Apr;42(4):245-254 [PMID: 27932073]
Cell Death Dis. 2013 Sep 05;4:e790 [PMID: 24008734]
Brain. 1991 Oct;114 ( Pt 5):2283-301 [PMID: 1933245]
ACS Chem Neurosci. 2022 Mar 16;13(6):818-833 [PMID: 35196855]
Glia. 2021 Jun;69(6):1413-1428 [PMID: 33506583]
J Biol Chem. 2014 Nov 21;289(47):32926-36 [PMID: 25288801]
Front Pharmacol. 2020 May 08;11:612 [PMID: 32457616]
J Cell Biol. 2009 Oct 5;187(1):61-70 [PMID: 19805629]
Lancet Neurol. 2009 Dec;8(12):1128-39 [PMID: 19909911]
J Cell Mol Med. 2020 Jul;24(14):8078-8090 [PMID: 32521573]
Hum Mol Genet. 1998 Aug;7(8):1229-34 [PMID: 9668163]
J Biol Chem. 2015 Nov 6;290(45):27425-27437 [PMID: 26416893]
Mol Psychiatry. 2023 Jul;28(7):2878-2893 [PMID: 36316366]
Nat Immunol. 2014 Aug;15(8):727-37 [PMID: 24952505]
Cell Death Differ. 2018 Nov;25(11):2037-2049 [PMID: 29786071]
JAMA Neurol. 2014 Apr;71(4):505-8 [PMID: 24493463]
Neurology. 2019 Mar 5;92(10):e1029-e1040 [PMID: 30770430]
J Neurosci. 2010 Nov 24;30(47):15811-20 [PMID: 21106820]
JCI Insight. 2022 Apr 22;7(8): [PMID: 35451371]
J Neurol Sci. 2002 May 15;197(1-2):9-18 [PMID: 11997061]
J Immunol. 2011 Jul 15;187(2):613-7 [PMID: 21677136]
Trends Mol Med. 2017 Feb;23(2):165-180 [PMID: 28109721]
Biochem J. 2009 Jan 1;417(1):1-13 [PMID: 19061483]
Nat Genet. 2001 Nov;29(3):301-5 [PMID: 11687797]
Neurosci Lett. 2020 Sep 25;736:135279 [PMID: 32726591]
Lancet Neurol. 2014 Aug;13(8):788-94 [PMID: 25030513]
Cell Res. 2015 Dec;25(12):1285-98 [PMID: 26611636]
Mov Disord. 2012 Apr 15;27(5):617-26 [PMID: 22508280]
ACS Chem Neurosci. 2017 Oct 18;8(10):2194-2201 [PMID: 28653829]
Int J Neurosci. 2013 Oct;123(10):711-8 [PMID: 23594042]
Transl Neurodegener. 2015 Oct 12;4:19 [PMID: 26464797]
Neurology. 1988 Aug;38(8):1285-91 [PMID: 3399080]
Cell Metab. 2016 Jul 12;24(1):158-66 [PMID: 27374498]
J Neuroimmunol. 2009 Feb 15;207(1-2):101-6 [PMID: 19162335]
World J Exp Med. 2014 Aug 20;4(3):27-37 [PMID: 25254187]
J Neuroinflammation. 2015 Jan 28;12:18 [PMID: 25626361]
Front Neurol. 2018 Mar 19;9:135 [PMID: 29615953]
Nat Rev Immunol. 2010 Mar;10(3):210-5 [PMID: 20168318]
Acc Chem Res. 2006 Sep;39(9):628-34 [PMID: 16981679]
Lancet Neurol. 2015 Apr;14(4):406-19 [PMID: 25792099]
Purinergic Signal. 2019 Mar;15(1):119-123 [PMID: 30547277]
J Neuroinflammation. 2019 Dec 3;16(1):250 [PMID: 31796095]
Immunity. 2016 Oct 18;45(4):802-816 [PMID: 27692610]
Neurosci Lett. 1994 Oct 24;180(2):147-50 [PMID: 7700568]
J Exp Med. 2019 Nov 4;216(11):2562-2581 [PMID: 31467036]
J Parkinsons Dis. 2017;7(s1):S11-S19 [PMID: 28282815]
Med Sci (Basel). 2017 Oct 13;5(4): [PMID: 29099039]
Nat Immunol. 2014 Aug;15(8):738-48 [PMID: 24952504]
J Immunol. 1991 Mar 1;146(5):1541-6 [PMID: 1993844]
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7671-6 [PMID: 24817693]
Cell Rep. 2017 Dec 19;21(12):3414-3426 [PMID: 29262323]
Mol Biol Cell. 1999 May;10(5):1463-75 [PMID: 10233156]
Neurol Ther. 2018 Jun;7(1):59-85 [PMID: 29243029]
Sci Rep. 2017 Jul 19;7(1):5845 [PMID: 28724943]
Immunol Rev. 2020 Sep;297(1):26-38 [PMID: 32729116]
Blood. 2011 Apr 7;117(14):3720-32 [PMID: 21304099]
NPJ Parkinsons Dis. 2021 Jan 4;7(1):2 [PMID: 33398042]
Nature. 2015 Oct 29;526(7575):666-71 [PMID: 26375259]
J Cell Biochem. 2019 Apr;120(4):5160-5168 [PMID: 30320900]
Cell. 2016 Feb 11;164(4):603-15 [PMID: 26871627]
Neuron. 2022 Aug 3;110(15):2422-2437.e9 [PMID: 35654037]
Circulation. 2013 Aug 6;128(6):632-42 [PMID: 23838163]
Neuropathol Appl Neurobiol. 2000 Feb;26(1):2-10 [PMID: 10736062]
J Neuroinflammation. 2021 Dec 2;18(1):280 [PMID: 34856990]
Am J Hum Genet. 2000 May;66(5):1693-8 [PMID: 10741953]
Brain Res. 1984 Feb 6;292(2):390-4 [PMID: 6607092]
J Exp Med. 2021 May 3;218(5): [PMID: 33710283]
Diabetes Metab Syndr Obes. 2019 Sep 20;12:1931-1942 [PMID: 31571967]
Dev Neurobiol. 2017 May;77(5):625-642 [PMID: 27314460]
J Immunol. 2009 Jul 15;183(2):787-91 [PMID: 19570822]
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7858-63 [PMID: 27339137]
Neurobiol Dis. 2022 Sep;171:105804 [PMID: 35764290]
Nature. 2011 Oct 16;479(7371):117-21 [PMID: 22002608]
Exp Neurol. 2015 Nov;273:24-35 [PMID: 26222336]
J Pharmacol Exp Ther. 2001 Oct;299(1):187-97 [PMID: 11561079]
Nature. 2015 Oct 29;526(7575):660-5 [PMID: 26375003]
Nat Rev Immunol. 2013 Jun;13(6):397-411 [PMID: 23702978]
J Neurosci. 2011 Aug 17;31(33):11879-88 [PMID: 21849548]
Neuroepidemiology. 2013;40(3):195-210 [PMID: 23363936]
EMBO J. 2016 Aug 15;35(16):1766-78 [PMID: 27418190]
Nat Commun. 2014 Sep 30;5:4977 [PMID: 25266676]
Brain. 2020 May 1;143(5):1414-1430 [PMID: 32282893]
J Immunol. 2016 Oct 15;197(8):3315-3325 [PMID: 27638862]
Nature. 2016 Jul 7;535(7610):111-6 [PMID: 27281216]
Neurosci Lett. 1995 Dec 29;202(1-2):17-20 [PMID: 8787820]
J Proteome Res. 2017 Jan 6;16(1):170-178 [PMID: 27684284]
Nat Rev Neurosci. 2001 Oct;2(10):734-44 [PMID: 11584311]
J Exp Med. 1995 Nov 1;182(5):1447-59 [PMID: 7595215]
J Neuroimmune Pharmacol. 2009 Dec;4(4):462-75 [PMID: 19669892]
Front Mol Neurosci. 2018 Sep 04;11:309 [PMID: 30233311]
Aging (Albany NY). 2020 May 19;12(10):9405-9426 [PMID: 32432571]
J Mol Med (Berl). 2013 Jun;91(6):673-81 [PMID: 23546523]
Nature. 2018 May;557(7703):62-67 [PMID: 29695864]
Nat Rev Neurosci. 2018 Oct;19(10):610-621 [PMID: 30206330]
Toxicol Sci. 2017 Sep 1;159(1):64-75 [PMID: 28903492]
J Immunol. 2021 Oct 15;207(8):2143-2154 [PMID: 34507948]
Ther Adv Neurol Disord. 2012 Jan;5(1):13-22 [PMID: 22276073]
Fluids Barriers CNS. 2020 Nov 18;17(1):69 [PMID: 33208141]
Cell Death Differ. 2018 Mar;25(3):486-541 [PMID: 29362479]
Sci Transl Med. 2012 Feb 15;4(121):121ps3 [PMID: 22344685]
Ann Neurol. 2010 Jun;67(6):715-25 [PMID: 20517933]
Mov Disord. 2020 Oct;35(10):1721-1722 [PMID: 32815213]
Sci Signal. 2012 May 22;5(225):ra38 [PMID: 22623753]
J Cereb Blood Flow Metab. 2014 Apr;34(4):621-9 [PMID: 24398937]
Front Immunol. 2022 Apr 06;13:766919 [PMID: 35464490]
Nature. 2011 Jan 13;469(7329):221-5 [PMID: 21124315]
Front Mol Neurosci. 2020 Sep 17;13:166 [PMID: 33071753]
Nat Rev Immunol. 2016 Jul;16(7):407-20 [PMID: 27291964]
Neurol Neuroimmunol Neuroinflamm. 2015 May 14;2(4):e109 [PMID: 26020059]
Rheumatology (Oxford). 2009 Dec;48(12):1618-9 [PMID: 19828598]
Nature. 2016 Feb 18;530(7590):354-7 [PMID: 26814970]
J Biochem. 2017 Jun 1;161(6):503-512 [PMID: 28096454]
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9587-92 [PMID: 27482083]
Nat Chem Biol. 2019 Jun;15(6):556-559 [PMID: 31086327]
Nature. 2005 Apr 28;434(7037):1138-43 [PMID: 15858576]
J Neuroinflammation. 2018 Sep 27;15(1):282 [PMID: 30261895]
J Neuroinflammation. 2018 Jul 2;15(1):193 [PMID: 29966531]
J Neurol Neuromedicine. 2016;1(7):1-5 [PMID: 27990499]
PLoS One. 2013 Nov 21;8(11):e81785 [PMID: 24278459]
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10480-5 [PMID: 22699511]
Semin Immunol. 2018 Dec;40:61-73 [PMID: 30268598]
Immunity. 2001 Nov;15(5):825-35 [PMID: 11728343]
Science. 2006 Oct 6;314(5796):130-3 [PMID: 17023659]
NPJ Parkinsons Dis. 2018 Aug 15;4:24 [PMID: 30131971]
Annu Rev Pathol. 2019 Jan 24;14:239-261 [PMID: 30355155]
Alzheimers Res Ther. 2013 Aug 27;5(4):39 [PMID: 23981712]
J Exp Med. 2019 Jun 3;216(6):1411-1430 [PMID: 31036561]
Acta Neuropathol. 2017 Oct;134(4):629-653 [PMID: 28527044]
Sci Transl Med. 2018 Oct 31;10(465): [PMID: 30381407]
NPJ Parkinsons Dis. 2018 Jul 10;4:21 [PMID: 30003140]
J Exp Med. 2017 May 1;214(5):1351-1370 [PMID: 28404595]

Grants

  1. F31 ES030982/NIEHS NIH HHS
  2. R01 ES024745/NIEHS NIH HHS
  3. R01 ES033462/NIEHS NIH HHS

MeSH Term

Humans
Inflammasomes
NLR Family, Pyrin Domain-Containing 3 Protein
Neurodegenerative Diseases
Cell Death
Inflammation

Chemicals

Inflammasomes
NLR Family, Pyrin Domain-Containing 3 Protein
Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Word Cloud

Similar Articles

Cited By